Tags : Kadmon

M&A

Sanofi to Acquire Kadmon for ~$1.9B

Shots: Sanofi to acquire Kadmon for $9.50/share in cash making a total equity value of ~ $1.9B with a premium of 79% to a closing price of $5.30 on Sept 07, 2021. The acquisition is expected to be completed in Q4’21 The acquisition will bolster Sanofi’s transplant business with the addition of Kadmon’s Rezurock to […]Read More

Insights+

Insights+: The US FDA New Drug Approvals in July 2021

The US FDA has approved 6 NDAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 43 novel products in 2021 Additionally, last year in 2020, the US FDA has approved 121 […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (December 23-27, 2019)

1. Luye Pharma Reports Submission of NDA to the US FDA for LY03005 Published: Dec 26, 2019 | Tags: FDA, Luye Pharma, LY03005, NDA, reports, Submission, US 2. Immunomedics Reports the US FDA’s Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer Published: Dec 26, 2019 | Tags: Acceptance, BLA, FDA, Immunomedics, […]Read More

Pharma

Kadmon and Meiji Collaborate to Form JV for the Development

Shots: Kadmon to receive ~$29M as development, regulatory & commercial milestones with royalties on sales of KD025 in Japan and certain other Asian countries The JV, named as Romeck Pharma has the HQ in Japan with shared oversight between Kadmon and Meiji KD025 is ROCK2 inhibitor with the potential to treat inflammatory and fibrotic diseases, […]Read More